Watch for bounce. This company is on stealth mode at the moment but watch for breakout soon as white candles start forming. Bounce is due here soon. The company has great potential going into 2006. They are in an industry that is expected to branch out in the near future. Undervalued company deserves some attention. Heres a little more on Calbatech:
CalbaTech is focused on developing and providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. In addition to growth through acquisition, CalbaTech, comprised of three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, is building an experienced and innovative scientific staff, including several notable members of its Scientific Advisory Board that intend to contribute innovation in areas of biological discovery.
interesting !
2005-12-20 05:00:11
CalbaTech's Subsidiary, LifeStem, Inc., Contracts With Solana MedSpas to Exclusively Offer Its Stem Cell Microbank(TM) to Bank Adult Stem Cells Through Solana MedSpas' National Network
IRVINE, Calif., Dec. 20 /PRNewswire-FirstCall/ -- CalbaTech, Inc.
(OTC Bulletin Board: CLBE), an emerging life sciences company
(http://www.CalbaTech.com) concentrating on providing products and platforms
to the research market for biotech and pharmaceutical companies and to
academic institutions, today announced that its wholly owned subsidiary,
LifeStem, Inc., has reached an agreement with Solana MedSpas
(http://www.solanamedspas.com), the nation's foremost developer and syndicator
of medical spas, to exclusively offer LifeStem's Stem Cell MicroBank(TM)
Service through Solana MedSpas' national network.
In the definitive agreement, LifeStem's Stem Cell MicroBank(TM) will
initially be offered in six Solana MedSpas network locations in Southern
California. Solana MedSpas expects to have as many as 70 locations open by
the end of 2006 and intends to offer the Stem Cell Microbank Service at all
locations. "We are extremely pleased that we have formalized an agreement
with Solana MedSpas," says LifeStem President Dan Fulkerson, "and are
confident that many individuals within the Solana MedSpas client base will
take advantage of our Stem Cell MicroBank(TM) Service."
Fulkerson continued, "By beginning with six locations and by adding new
locations as Solana MedSpas debuts them, our conservative estimates over the
first 12 months of operations project revenues in excess of $3 million, with
the potential to exceed $25 million in the next couple of years. We're
looking forward to expanding our microbanking model into the growing Solana
MedSpas network."
In addition to serving the Solana MedSpas client base, LifeStem is
planning an aggressive marketing program of its Stem Cell Microbank(TM)
Service, outside of Solana's efforts, which will reach more potential clients.
"We are delighted to finalize our agreement with LifeStem," says John
Buckingham, CEO and co-founder of Irvine, Calif.-based Solana MedSpas. "We
are now ready to move to the beta test phase at selected medspa locations,"
Buckingham adds, noting that Solana MedSpas will the first medspa network to
offer an adult stem cell collection service. "As Solana MedSpas continue to
orchestrate the marriage of healthcare product innovation with our ever
expanding medspa distribution channel, the addition of LifeStem's Stem Cell
MicroBank(TM) Service to our locations, not only positions Solana MedSpas as
unique vis-a-vis the competition, but it represents the next logical step in
the realization of our vision and mission as a syndicator of medical spas."
About CalbaTech
Recent contract is only one of multiple contracts expected to be announced in the upcoming months. I truly think the price on this stock will appreciate soon. Quaterly profits are already looking good and the company is forecasting record breaking profits in '06.
The market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 due to the growth of new cellular therapeutics as well as clinical applications. LifeStem's strategy is to leverage CalbaTech's infrastructure of companies to obtain a leadership position in the emerging stem cells arena and become a preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services.
Happy Holidays all.
Doing more research on my companies..
The market for stem cell technology is currently $500 million, and has been estimated to grow to $30 billion by the year 2010 due to the growth of new cellular therapeutics as well as clinical applications. LifeStem's strategy is to leverage CalbaTech's infrastructure of companies to obtain a leadership position in the emerging stem cells arena and become a preferred provider of adult stem cells to the clinical researcher as part of a comprehensive package of stem cell based services.
The one thing about high quality penny stocks is that they rarely ever run high and fast at the same time. Most are slow growth but strong investments to certain levels. As science progresses, anyone can see that stem cell technology is going to be a major contributor but many here may believe that is all CalbaTech does and that's not true. They are deep into DNA and molecular research also.
CalbaTech is pursuing a strategy of combining products and technologies, and the companies that provide them, into the following divisions: 1) Molecular Applications; 2) Research Reagents; and 3) Cellular Therapeutics. By pursuing such a strategy, each division should produce value added and increasing returns on shareholders' investment through cross marketing of products and geographic expansion, as well as to achieve product enhancement and efficiency.
http://www.agoracom.com/brokerfactsheet/clbebfs12.pdf
For both long holders and short term traders, I think this will be one last chance to accumulate shares at this price. This stock is setting up for a trend reversal and nice forward momentum. Early next year, they are expected to report solid net profits for 05. Friday, a bullish candle was formed, indicating that this could be setting up for a change in direction..
http://www.americanbulls.net/StockPage.asp?CompanyTicker=CLBE&MarketTicker=OTC&TYP=S
http://biz.yahoo.com/e/051223/clbe.ob8-k.html
Great Tax-Selling buying opportunity! 2006 will be explosive for stem cell stocks! I am back in with a .02325 average... Great long term prostects and also been a Great trading stock this past year... :) GLTA
Quote from: B Hathaway on December 26, 2005, 11:01:12 AM
For both long holders and short term traders, I think this will be one last chance to accumulate shares at this price. This stock is setting up for a trend reversal and nice forward momentum. Early next year, they are expected to report solid net profits for 05. Friday, a bullish candle was formed, indicating that this could be setting up for a change in direction..
http://www.americanbulls.net/StockPage.asp?CompanyTicker=CLBE&MarketTicker=OTC&TYP=S
http://biz.yahoo.com/e/051223/clbe.ob8-k.html
Resistence Levels... strong resistence at .03 then we will trade to the .05 level rather easily...then not much resistence upwards and that will be later this year or depending on how fast they get operations going especially with the agressive promoting of the LifeStem Stem Cell MicroBank service...GLTA
resist. 0.22 9
resist. 0.20 3
resist. 0.15 2
resist. 0.08 2
resist. 0.07 4
resist. 0.05 11
resist. 0.03 34
Quote from: GatewayStocks on December 28, 2005, 02:07:40 PM
Great Tax-Selling buying opportunity! 2006 will be explosive for stem cell stocks! I am back in with a .02325 average... Great long term prostects and also been a Great trading stock this past year... :) GLTA[/b]
Yes, I agree Gateway,
This company has strong potential going into 2006. With new p/r's rumored to be out soon, bothe investors and traders will realize that this company is no fluke. Look for substantial net profits coming and do your own DD to understand why shareholders like me are anticipating a colossal sales growth report for 2005. Rumor has it that this setting up for a nice run real soon. Reversal day confirmed today with previous day low being followed by a higher close than the previous day's high. Huge volume this week also confirms that this stock is getting a lot of attention.
This is a 3 year Chart...looks like it is in a long term downtrend...i will stay away
Ket,
Calbatech, Inc. (CLBE) is poised to emerge ahead of its current condition starting early next year. The stock has been depreciated this past year due to poor net income for 2004. This year however, they have reported positive record earning statements and are projecting even greater earnings growth for 2006. They hold numerous patents on all of its proprietary technologies. Their subsidiary, Lifestem, Inc. is acquiring more contracts to whom they can offer their Stem Cell Microbank. Calbatech has opened the doors for great opportunities for 2006. Here are some of their key numbers:
Company Type Public (OTC: CLBE)
Fiscal Year-End December
2004 Sales (mil.)-- $0.3
1-Year Sales Growth-- 2,408.3%
2004 Net Income (mil.)-- ($2.7)
2004 Employees-- 19
1-Year Employee Growth-- 137.5%
+21% :) Watch for strong trend to continue next week. Volume has been strong all week. Still not too late to get in as we expect good news from this company soon! No time to hesitate. Discounted shares wont last.
broke .03 resistence HOD .034... Looking good going into next year... no tax selling/selling of any kind last 2 days to speak of. That .03 break today was huge 8)
B Hathaway...I agree, Microbank contracts will come from all over if they promote agressivily as they stated they will... I can't make projections but the way it is set up there could be dosens of deals just on microbank alone...This doesn't even include their other products and patents... CLBE was about the only stem cell stock up the past 2 days... I look for great news coming very soon and a continous flow...Numbers for 2005 mark a distinct turnaround year for CLBE and 06 is 10 times more promising with the groundwork laid...GLTA ;D
Quote from: B Hathaway on December 30, 2005, 05:00:14 AM
Ket,
Calbatech, Inc. (CLBE) is poised to emerge ahead of its current condition starting early next year. The stock has been depreciated this past year due to poor net income for 2004. This year however, they have reported positive record earning statements and are projecting even greater earnings growth for 2006. They hold numerous patents on all of its proprietary technologies. Their subsidiary, Lifestem, Inc. is acquiring more contracts to whom they can offer their Stem Cell Microbank. Calbatech has opened the doors for great opportunities for 2006. Here are some of their key numbers:
Company Type Public (OTC: CLBE)
Fiscal Year-End December
2004 Sales (mil.)-- $0.3
1-Year Sales Growth-- 2,408.3%
2004 Net Income (mil.)-- ($2.7)
2004 Employees-- 19
1-Year Employee Growth-- 137.5%
Website Updated... also check out thier Molecula & KD Medical website's.
http://www.calbatech.com/
http://www.molecula.com/
http://www.kdmedical.com/new_index.asp
RSI formed a BullCross and MACD is very bullish as the charts are mostly all turning bullish... GLTA
another day of good volume...need to hear something from the company
Yup. I have a good feeling we will soon gateway. They're awaiting patents and their subsidaries are aquiring contracts. I believe this will make a nice run up to .07-.10 by the end of the first quarter. Patience is virtue.
MACD Bottom Bullish Divergence Pattern formed wich is very bullish...If we can close up tomorrow it will indicate a Buy on the Candlesticks. JMHO & GL
Nice Investor fact Sheet;
http://www.agoracom.com/brokerfactsheet/clbebfs12.pdf
Rumor has it that theres news coming out soon. As I've mentioned on another, this is a great mid-long term invesment, wether news is do out soon or not. The Company believes that adult stem cells have tremendous potential to promote the regeneration of dead or diseased cardiac tissue. They have filed patent applications for its Stem Cell Delivery Device. If, approved, the patents will allow for the Device and Methods for Treatment of Necrotic Tissue using Stem Cells.
This is a not another junky catchpenny. They sell products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions. They are engaged in a business that will play a huge roll in stem cell developments this year. IMO, anything under a nickle is a bargain. Those holding on tight to their shares will see appreciation in due time.
Solid week IMO. Closed higher than it did last week and volume picked up on Friday. News is expected from Calbatech for not cetain if it will be released this month or the next. A supply with information on what the company is up to would be nice. We'll just hae to wait and see.
40 % up without news....only on rumors ?
edit : 140 % up :o
CLBE is in the early stages of a GREAT run people. Alerted at .03 and now .09
Just heating up, IMO. This will be trading in higher rangesd next week. Great week for those who got in and held with patience. But this is only the start...
Still no news and I see people starting to bash it on other boards...buy the dips..volume decreased today and I can see it drift lower on no news but that will be a buying opp...JMHO and GL
CLBE: CalbaTech Posts Letter to Shareholders on Achievements, Future Business Strategies
Tuesday June 13, 5:00 am ET
IRVINE, Calif., June 13 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE - News), an emerging life sciences company (http://www.CalbaTech.com ) concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech, pharmaceutical research market and to academic institutions, today in a letter to all shareholders said that a comparison of sixteen companies in the stem cell arena showed CalbaTech third in EBITDA (Earnings Before Income Taxes, Depreciation and Amortization) and first in average daily trading volume.
ADVERTISEMENT
However, the study shows CalbaTech had the second lowest market capitalization. "We believe this means that CalbaTech has tremendous stock upside potential. If our revenues and profits begin to reach pro-forma projections, particularly with LifeStem's Stem Cell MicroBank(TM) Service to open this month, the stock price should respond accordingly," wrote James DeOlden, CEO. The entire letter follows:
Dear Fellow Shareholder:
We at CalbaTech, Inc. thank you for your investment in our Company. The goals at CalbaTech are two-fold: To acquire revenue generating Life Science "tools" companies, that provide products and platforms to researchers, forming a profitable base by which to provide the Company with cash flow and allow it to seek higher reward projects; and to develop those higher reward projects that will provide the opportunity for a greater upside to our shareholders. We believe we are well on our way to accomplishing both of these goals.
Research Reagents Division
In 2003, we acquired Molecula, LLC, a company in Sterling, Virginia, that sold transfection products. In 2004, we acquired KD Medical, a company in Columbia, Maryland, that supplied research products to more than 300 National Institute of Health (NIH) laboratories, as well as most of the major pharmaceutical companies. While both were generating revenue when acquired, neither was profitable. In the past year, we have worked diligently to make the Research Reagents Division the profitable base we intended.
The first step was to incorporate a new Molecula, Inc. in Nevada, and then combine the operations of Molecula and KD Medical into one facility to more efficiently capitalize on their synergistic operations. Next, marketing efforts were coordinated to take advantage of common markets. Finally, redundancies in the management teams of the two companies were eliminated. The result is that the Research Reagents Division reported a net profit for 2005 and again in the first quarter of 2006. Furthermore, this Division is reporting a 25% growth in revenue for the quarter ended March 31, 2006, as compared to the same period in 2005.
The next move is, literally, a move, into a new location. This Division will be moving into a new facility with two validated Class 100 clean rooms and a complete quality control laboratory that will be used to grow revenues in two different ways. One clean room will be used to increase the manufacturing capabilities of the KD Medical product offerings, so as to manufacture a higher quality of product, and to expand the current custom product offerings to the NIH as well as major universities and pharmaceutical companies. The second clean room will be utilized for other potential growth in revenue by allowing the Division to perform contract research for the many pharmaceutical companies located in this region.
Finally, the Research Reagents Division should also experience growth and greater profitability due to a recent understanding with a large media company to produce some of KD's routine media products. This is intended to allow KD to more aggressively sell these routine products, with greater profitability due to a decrease in redundant labor, and to enter markets that were previously unavailable due to cost competitiveness. This should result in an increase in revenues and allow KD to focus more attention to manufacturing custom products.
In summary, we believe that the Research Reagents Division has become a steady, growing, profitable foundation upon which we can build a greater return for our shareholders.
Cellular Therapies Division - LifeStem
In 2004, we purchased I-Stem from Dr. Jason R. Van Tassell, M.D. I-Stem owned the intellectual property to the Stem Cell Delivery Device, an endoscopic device capable of delivering adult stem cells directly to infarcted cardiac tissue. Dr. Van Tassel created the concept after hearing about an Illinois teenager who became a cardiac cripple after being shot in the heart by a nail gun. The teenager had adult stem cells injected into his blood stream resulting in cardiac tissue regeneration. While the teenager does not have completely normal cardiac function, the results were significant, allowing him functionality. Dr. Van Tassel reasoned that if stem cells injected into peripheral blood could cause significant cardiac tissue regeneration, then cells injected directly into the cardiac tissue would have even greater efficacy.
Subsequently the Company formed LifeStem, Inc., a wholly-owned subsidiary, to further I-Stem as well as to enter the new emerging field of banking adult stem cells for autologous use. This was determined after canvassing current stem cell banking services and realizing that there was a tremendous void to be filled, as the market had competitors at opposite poles. There are several companies collecting umbilical cord blood from newborns, which contain fertile stem cells, and there are other companies that are collecting autologous stem cells from adults in extremely inconvenient, invasive, costly, and time consuming ways. The former only helps those of the generation being born today whose parents have the foresight to take advantage of storing cord blood, and the latter does not provide non-invasive and convenient collection and storage of adult stem cells at a reasonable price.
We also determined that there were not any companies offering to collect adult stem cells from more than one tissue source. Some stem cells are more likely to develop into blood cells and similarly related tissues, while others are more likely to develop into bone, cartilage or muscle tissue. We therefore developed the process of harvesting stem cells in micro quantities to be cryopreserved for future transplantation into the client. We filed a patent application for our Stem Cell MicroBank(TM) Service, which is promulgated on the belief that it is unnecessary to collect an amount of stem cells sufficient to fully reconstitute one's entire immune system at the time of collection. LifeStem's Adult Stem Cell MicroBank(TM) is the only company to offer "micro" collections of stem cells from two different tissue sources thereby offering greater potential for treatments for multiple diseased conditions.
To a large degree, we believe that the adult stem cell collection and storage market mirrors the cosmetic surgery market, with its emphasis on proactive and preventative healthcare. People likely to have cosmetic surgery are concerned about quality of and longevity of life, they are health conscious, college-educated, and tend to seek non-traditional medical services. To this end, in December 2005, we signed a distribution agreement with Solana MedSpas, a developer and syndicator of medical spas, with 25 medspas currently open and operating and plans for more than 50 additional locations to open during 2006. In accordance with this agreement, adult stem cell collections will be performed at medspa locations using our Stem Cell Microbank(TM) Service. We are also working to contract with physician's offices to carry our Stem Cell MicroBank(TM) Service and believe that cosmetic surgeons, cardiologists, and orthopedists will be excellent distribution sites. With these agreements, we believe we will be ready to make an explosive entry into this marketplace as we perform the first collections in June.
First Quarter 2006 Financial Results/Stock Performance
The first quarter of this year is reflective of our belief in the CalbaTech model, as well as the actions we have taken over the past year. KD Medical, Molecula, and another of our other wholly-owned subsidiaries, Molecularware, Inc., all were profitable and as a whole experienced a 25% growth in revenue. LifeStem is primed for success as the pricing and cost structure of the Stem Cell Microbank(TM) Service will be profitable from each collection.
Recently, an industry source published information regarding each of the public companies competing in the stem cell arena. Of the sixteen companies listed, CalbaTech was listed third in EBITDA (Earnings Before Income Taxes, Depreciation and Amortization), and first in average daily trading volume, yet had the second lowest market capitalization. We believe this means that CalbaTech has tremendous stock upside potential. If our revenues and profits begin to reach our pro-forma projections, particularly with LifeStem's Stem Cell MicroBank(TM) Service set to open in June, the price of our stock should respond accordingly.
We have put the building blocks in place and have begun building a truly successful company. We are pleased that you have chosen to invest in CalbaTech. Thank you for the trust and continued support.
Sincerely,
James DeOlden
Chief Executive Officer
Note: Certain statements in this President's Letter may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
Contact:
Paul Knopick
E&E Communications
(949) 707-5365
[email protected]
Looks good for next week and should be getting news on the MicroBank full launch...My, guess is that we see a lot of green going into the rest of the year...Congrats to all who have been buying down here :) 8)
From last PR...this is going to be Huge... 8)
"We are also working to contract with physician's offices to carry our Stem Cell MicroBank(TM) Service and believe that cosmetic surgeons, cardiologists, and orthopedists will be excellent distribution sites. With these agreements, we believe we will be ready to make an explosive entry into this marketplace as we perform the first collections in June." ;D
RSI Ready to turn BULLISH once we get a cross of 50....GLTA 8)
.043 break of 50 will be big signal of trend reversal and breakout!!! 8)
Breaking out! Real-Time!
News expected after close or Wen...but, soon
CalbaTech, Inc. ( OTCBB: CLBE - http://finance.yahoo.com/q?s=CLBE.OB )
CalbaTech, Inc., an emerging life sciences company concentrating on banking adult stem cells for possible future therapeutic uses and providing products and platforms to the biotech, pharmaceutical research market and to academic institutions, in a letter to all shareholders said that a comparison of sixteen companies in the stem cell arena showed CalbaTech third in EBITDA (Earnings Before Income Taxes, Depreciation and Amortization) and first in average daily trading volume.
However, the study shows CalbaTech had the second lowest market capitalization. "We believe this means that CalbaTech has tremendous stock upside potential. If our revenues and profits begin to reach pro-forma projections, particularly with LifeStem's Stem Cell MicroBank(TM) Service to open this month, the stock price should respond accordingly," wrote James DeOlden, CEO. The entire letter follows:
Dear Fellow Shareholder:
We at CalbaTech, Inc. thank you for your investment in our Company. The goals at CalbaTech are two-fold: To acquire revenue generating Life Science "tools" companies, that provide products and platforms to researchers, forming a profitable base by which to provide the Company with cash flow and allow it to seek higher reward projects; and to develop those higher reward projects that will provide the opportunity for a greater upside to our shareholders. We believe we are well on our way to accomplishing both of these goals.
Research Reagents Division
In 2003, we acquired Molecula, LLC, a company in Sterling, Virginia, that sold transfection products. In 2004, we acquired KD Medical, a company in Columbia, Maryland, that supplied research products to more than 300 National Institute of Health (NIH) laboratories, as well as most of the major pharmaceutical companies. While both were generating revenue when acquired, neither was profitable. In the past year, we have worked diligently to make the Research Reagents Division the profitable base we intended.
The first step was to incorporate a new Molecula, Inc. in Nevada, and then combine the operations of Molecula and KD Medical into one facility to more efficiently capitalize on their synergistic operations. Next, marketing efforts were coordinated to take advantage of common markets. Finally, redundancies in the management teams of the two companies were eliminated. The result is that the Research Reagents Division reported a net profit for 2005 and again in the first quarter of 2006. Furthermore, this Division is reporting a 25% growth in revenue for the quarter ended March 31, 2006, as compared to the same period in 2005.
The next move is, literally, a move, into a new location. This Division will be moving into a new facility with two validated Class 100 clean rooms and a complete quality control laboratory that will be used to grow revenues in two different ways. One clean room will be used to increase the manufacturing capabilities of the KD Medical product offerings, so as to manufacture a higher quality of product, and to expand the current custom product offerings to the NIH as well as major universities and pharmaceutical companies. The second clean room will be utilized for other potential growth in revenue by allowing the Division to perform contract research for the many pharmaceutical companies located in this region.
Finally, the Research Reagents Division should also experience growth and greater profitability due to a recent understanding with a large media company to produce some of KD's routine media products. This is intended to allow KD to more aggressively sell these routine products, with greater profitability due to a decrease in redundant labor, and to enter markets that were previously unavailable due to cost competitiveness. This should result in an increase in revenues and allow KD to focus more attention to manufacturing custom products.
In summary, we believe that the Research Reagents Division has become a steady, growing, profitable foundation upon which we can build a greater return for our shareholders.
Cellular Therapies Division - LifeStem
In 2004, we purchased I-Stem from Dr. Jason R. Van Tassell, M.D. I-Stem owned the intellectual property to the Stem Cell Delivery Device, an endoscopic device capable of delivering adult stem cells directly to infarcted cardiac tissue. Dr. Van Tassel created the concept after hearing about an Illinois teenager who became a cardiac cripple after being shot in the heart by a nail gun. The teenager had adult stem cells injected into his blood stream resulting in cardiac tissue regeneration. While the teenager does not have completely normal cardiac function, the results were significant, allowing him functionality. Dr. Van Tassel reasoned that if stem cells injected into peripheral blood could cause significant cardiac tissue regeneration, then cells injected directly into the cardiac tissue would have even greater efficacy.
Subsequently the Company formed LifeStem, Inc., a wholly-owned subsidiary, to further I-Stem as well as to enter the new emerging field of banking adult stem cells for autologous use. This was determined after canvassing current stem cell banking services and realizing that there was a tremendous void to be filled, as the market had competitors at opposite poles. There are several companies collecting umbilical cord blood from newborns, which contain fertile stem cells, and there are other companies that are collecting autologous stem cells from adults in extremely inconvenient, invasive, costly, and time consuming ways. The former only helps those of the generation being born today whose parents have the foresight to take advantage of storing cord blood, and the latter does not provide non-invasive and convenient collection and storage of adult stem cells at a reasonable price.
We also determined that there were not any companies offering to collect adult stem cells from more than one tissue source. Some stem cells are more likely to develop into blood cells and similarly related tissues, while others are more likely to develop into bone, cartilage or muscle tissue. We therefore developed the process of harvesting stem cells in micro quantities to be cryopreserved for future transplantation into the client. We filed a patent application for our Stem Cell MicroBank(TM) Service, which is promulgated on the belief that it is unnecessary to collect an amount of stem cells sufficient to fully reconstitute one's entire immune system at the time of collection. LifeStem's Adult Stem Cell MicroBank(TM) is the only company to offer "micro" collections of stem cells from two different tissue sources thereby offering greater potential for treatments for multiple diseased conditions.
To a large degree, we believe that the adult stem cell collection and storage market mirrors the cosmetic surgery market, with its emphasis on proactive and preventative healthcare. People likely to have cosmetic surgery are concerned about quality of and longevity of life, they are health conscious, college-educated, and tend to seek non-traditional medical services. To this end, in December 2005, we signed a distribution agreement with Solana MedSpas, a developer and syndicator of medical spas, with 25 medspas currently open and operating and plans for more than 50 additional locations to open during 2006. In accordance with this agreement, adult stem cell collections will be performed at medspa locations using our Stem Cell Microbank(TM) Service. We are also working to contract with physician's offices to carry our Stem Cell MicroBank(TM) Service and believe that cosmetic surgeons, cardiologists, and orthopedists will be excellent distribution sites. With these agreements, we believe we will be ready to make an explosive entry into this marketplace as we perform the first collections in June.
First Quarter 2006 Financial Results/Stock Performance
The first quarter of this year is reflective of our belief in the CalbaTech model, as well as the actions we have taken over the past year. KD Medical, Molecula, and another of our other wholly-owned subsidiaries, Molecularware, Inc., all were profitable and as a whole experienced a 25% growth in revenue. LifeStem is primed for success as the pricing and cost structure of the Stem Cell Microbank(TM) Service will be profitable from each collection.
Recently, an industry source published information regarding each of the public companies competing in the stem cell arena. Of the sixteen companies listed, CalbaTech was listed third in EBITDA (Earnings Before Income Taxes, Depreciation and Amortization), and first in average daily trading volume, yet had the second lowest market capitalization. We believe this means that CalbaTech has tremendous stock upside potential. If our revenues and profits begin to reach our pro-forma projections, particularly with LifeStem's Stem Cell MicroBank(TM) Service set to open in June, the price of our stock should respond accordingly.
We have put the building blocks in place and have begun building a truly successful company. We are pleased that you have chosen to invest in CalbaTech. Thank you for the trust and continued support.
Sincerely,
James DeOlden Chief Executive Officer
Highlighted above is our big boy.... 8)
CLBE - CalbaTech
these links should show everyone investing in CLBE just exactly what they are about and why they are going to increase in value tremendously.For those here who remember our pick of BIPH from .09 to .20's as a strong buy and it ran to $3.60 within a few months and TDCP from the subs to $3's within the same year CLBE is projected to reach $2 to $4 range in the not so distant future.DD it closely and my personal contact with Paul in IR says a PR is due out any time now on the opening of the new MicroBank for stem cell collections.CLBE is an adult stem cell med sector company and there is no unethical restrictions.
http://www.calbatech.com/
http://www.kdmedical.com/
http://www.molecula.com/
http://www.molecula.com/new/index2.html
http://www.solanamedspas.com/home_B.htm
http://www.biotechnologyireland.com/...Q=BF_COMP_9172
Adult, not embryonic, stem cells better for research
http://www.statenews.com/op_article.phtml?pk=36817
http://english.chosun.com/w21data/ht...510060016.html
Catholic Church Funds Adult Stem Cell Research
first link is a couple years old but gives crystal clear direction for now.
http://www.21stcenturysciencetech.co...stem_cell.html
BIOLOGY & MEDICINE
The Case for Adult Stem Cell Research
CLBE will be more then fine soon,this is not a PR pumpiong company and the last share holder letter should make that clear,not to many CEO's will post in public the opinions he has,it would be far too liable if he didn't think it would come to past.
The first quarter of this year is reflective of our belief in the CalbaTech model, as well as the actions we have taken over the past year. KD Medical, Molecula, and another of our other wholly-owned subsidiaries, Molecularware, Inc., all were profitable and as a whole experienced a 25% growth in revenue. LifeStem is primed for success as the pricing and cost structure of the Stem Cell Microbank(TM) Service will be profitable from each collection.
Recently, an industry source published information regarding each of the public companies competing in the stem cell arena. Of the sixteen companies listed, CalbaTech was listed third in EBITDA (Earnings Before Income Taxes, Depreciation and Amortization), and first in average daily trading volume, yet had the second lowest market capitalization. We believe this means that CalbaTech has tremendous stock upside potential. If our revenues and profits begin to reach our pro-forma projections, particularly with LifeStem's Stem Cell MicroBank(TM) Service set to open in June, the price of our stock should respond accordingly.
We have put the building blocks in place and have begun building a truly successful company. We are pleased that you have chosen to invest in CalbaTech. Thank you for the trust and continued support.
Sincerely,
James DeOlden
Chief Executive Officer
Bid getting stronger...basing now real nice for a strong run!
L2 looks like were are going to open at resistance..bid building
this could easily break out into the double digits today and most of this is just PPS correction,CLBE should be trading at .15 to .20's without any new info and BTW heres a e-mail from IR
Paul Knopick
The company tells me to expect a news release detailing achievements in
stem cell banking soon.
Getting interesting again...possibly a breakout...depending how you draw the trendline at the top of the Candle or at the top of the Wick of the Candle. :)
Needs a little more volume.